Asian Cancer Research Group

The Asian Cancer Research Group, led by Pfizer, Eli Lilly, and Merck, has used whole-genome sequencing to identify recurrent, druggable mutations in hepatocellular carcinoma.

NEW YORK (GenomeWeb News) – A pair of studies in the early, online version of Nature Genetics are highlighting the types of genetic mutations that underlie the liver cancer hepatocellular carcinoma, including forms of the disease related to hepatitis B and hepatitis C virus infection.

Recently, Mao Mao, a research fellow at Pfizer Oncology Research who is working on several different cancer sequencing projects, spoke to In Sequence about the company's use of sequencing in drug development and the hurdles that still remain in implementing the technology in pharmaceutical research.

Through the formation of the Asian Cancer Research Group, Eli Lily, Merck, and Pfizer have also committed "to create one of the most extensive pharmacogenomic cancer databases known to date."

Researchers find that historical factors influence which genes are the most highly studied, the Atlantic reports.

The US National Science Foundation's new sexual harassment policy is to go into effect next month, according to Nature News.

Researchers report using genotyping to tie together illegal ivory shipments and trace them back to a handful of cartels, the New York Times reports.

In Nature this week: genomic ancestry analysis of Sardinians, current noncoding mutations in colorectal cancer, and more.